Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
Language English Country United States Media print
Document type Journal Article, Review
PubMed
28938795
DOI
10.1093/nutrit/nux047
PII: 4065280
Knihovny.cz E-resources
- Keywords
- dyslipidemia, lipid, nutraceuticals, position paper, recommendations,
- MeSH
- Dyslipidemias blood drug therapy epidemiology MeSH
- Phytochemicals administration & dosage blood pharmacokinetics MeSH
- Cholesterol, HDL blood MeSH
- Intestinal Absorption drug effects MeSH
- Liver drug effects metabolism MeSH
- Cardiovascular Diseases blood drug therapy epidemiology MeSH
- Cholesterol, LDL blood MeSH
- Drug Interactions MeSH
- Humans MeSH
- Evidence-Based Medicine MeSH
- Meta-Analysis as Topic MeSH
- Fatty Acids, Unsaturated administration & dosage blood pharmacokinetics MeSH
- Dietary Supplements * MeSH
- Observational Studies as Topic MeSH
- Probiotics administration & dosage pharmacokinetics MeSH
- Randomized Controlled Trials as Topic MeSH
- Risk Factors MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use MeSH
- Triglycerides blood MeSH
- Life Style MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Phytochemicals MeSH
- Cholesterol, HDL MeSH
- Cholesterol, LDL MeSH
- Fatty Acids, Unsaturated MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors MeSH
- Triglycerides MeSH
In recent years, there has been growing interest in the possible use of nutraceuticals to improve and optimize dyslipidemia control and therapy. Based on the data from available studies, nutraceuticals might help patients obtain theraputic lipid goals and reduce cardiovascular residual risk. Some nutraceuticals have essential lipid-lowering properties confirmed in studies; some might also have possible positive effects on nonlipid cardiovascular risk factors and have been shown to improve early markers of vascular health such as endothelial function and pulse wave velocity. However, the clinical evidence supporting the use of a single lipid-lowering nutraceutical or a combination of them is largely variable and, for many of the nutraceuticals, the evidence is very limited and, therefore, often debatable. The purpose of this position paper is to provide consensus-based recommendations for the optimal use of lipid-lowering nutraceuticals to manage dyslipidemia in patients who are still not on statin therapy, patients who are on statin or combination therapy but have not achieved lipid goals, and patients with statin intolerance. This statement is intended for physicians and other healthcare professionals engaged in the diagnosis and management of patients with lipid disorders, especially in the primary care setting.
Biotechnology Research Center Mashhad University of Medical Sciences Mashhad Iran
Department of Primary Care and Public Health Imperial College London UK
References provided by Crossref.org
